不同剂量阿托伐他汀对不稳定型心绞痛患者早期纤溶活性的影响  

Effect of atorvastatin with different dosage on fibrinolytic activity in early stage of patients with unstable angina pectoris

作　　者：邹广涛[1] 

机构地区：[1]河南省周口市中心医院内科,河南周口466000

出　　处：《中国心血管杂志》2006年第1期32-34,共3页Chinese Journal of Cardiovascular Medicine

摘　　要：目的探讨不同剂量阿托伐他汀对不稳定型心绞痛(UAP)患者早期纤溶活性的影响。方法90例UAP患者随机分为以下三组:①常规治疗组:给予阿司匹林、硝酸酯类;②10mg阿托伐他汀治疗组:在常规治疗的基础上,每晚口服阿托伐他汀10mg;③40mg阿托伐他汀治疗组:在常规治疗的基础上,每晚口服阿托伐他汀40mg。于治疗前、治疗3d及1周后分别空腹静脉采血,测定血清胆固醇、三酰甘油、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、组织型纤溶酶原激活剂(t-PA)及其抑制物(PAI-1)活性。结果治疗前三组间血脂及纤溶指标差异无显著性,治疗3d后,40mg组t-PA活性升高,PAI-1活性下降,治疗1周后,10mg及40mg组t-PA活性均升高,PAI-1活性均下降,差异有显著性,而血脂治疗前后无明显改变。结论阿托伐他汀能早期改善UAP患者异常的纤溶功能,大剂量应用作用更明显,且与调脂作用无关。Objective To investigate the effect of atorvastatin with two different dosages on fibrinolytic activity in early stage of patients with unstable angina pectoris（UAP）. Methods 90 patients with UAP were divided randomly into three groups： the control group treated with aspirin and nitrats only, 10mg and 40mg group given atorvastatin 10mg/d or 40mg/d at night respectively besides the treatment mentioned above. Plasma levels of cholesterol, triglyceride, low density lipoprotein, high density lipoprotein, tissue-type plasminogen activator （t-PA） and plasminogen activator inhibitor-1 （ PAI-1 ） were determined before admission and after 3, 7 days later. Results There was no significant difference of plasma levels of lipid and fibrinolytic activity in the three groups before treatment. After 3 days treatment, t-PA activity was increased and PAI-1 activity was decreased significantly in 40mg group. After 7 days treatment, same changes were observed in 10mg and 40mg groups. Plasma levels of lipid had no change after treatment in three groups. Conclusion Atorvastatin may increase fibrinolytic activity in early stage of UAP patients, and the effect of large dosage is obvious. This effect has no relations with that on lipid.

关 键 词：阿托伐他汀 不稳定型心绞痛 纤溶活性 

分 类 号：R541.4[医药卫生—心血管疾病]